FOXA1 and breast carcinoma: Based on these findings, the expression assessment of FOXA1 and GATA-3 in breast cancer patients can provide important clinical information – not only regarding the favourable prognostic nature and tumour behaviour, but the expression can also constitute an important tool to define and assess the luminal A subtype in breast cancer.